Format
Sort by
Items per page

Send to

Choose Destination

Best matches for SOMATROPIN/AE:

Growth hormone therapy with norditropin ( somatropin ) in growth hormone deficiency. Pawlikowska-Haddal A et al. Expert Opin Biol Ther. (2013)

Somatropin treatment of spinal muscular atrophy: a placebo-controlled, double-blind crossover pilot study. Kirschner J et al. Neuromuscul Disord. (2014)

Doping in sport: effects, harm and misconceptions. Birzniece V et al. Intern Med J. (2015)

Search results

Items: 1 to 20 of 847

1.

Medical Treatments for Acromegaly: A Systematic Review and Network Meta-Analysis.

Leonart LP, Ferreira VL, Tonin FS, Fernandez-Llimos F, Pontarolo R.

Value Health. 2018 Jul;21(7):874-880. doi: 10.1016/j.jval.2017.12.014. Epub 2018 Feb 8. Review.

PMID:
30005760
2.

The Use and Abuse of Human Growth Hormone in Sports.

Siebert DM, Rao AL.

Sports Health. 2018 Sep/Oct;10(5):419-426. doi: 10.1177/1941738118782688. Epub 2018 Jun 22. Review.

PMID:
29932857
3.

Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial.

Johannsson G, Feldt-Rasmussen U, Håkonsson IH, Biering H, Rodien P, Tahara S, Toogood A, Rasmussen MH; REAL 2 Study Group.

Eur J Endocrinol. 2018 May;178(5):491-499. doi: 10.1530/EJE-17-1073. Epub 2018 Mar 2.

4.

Chronic limb-threatening ischemia could benefit from growth hormone therapy for wound healing and limb salvage.

Caicedo D, Devesa P, Arce VM, Requena J, Devesa J.

Ther Adv Cardiovasc Dis. 2018 Feb;12(2):53-72. doi: 10.1177/1753944717745494. Epub 2017 Dec 22. Review.

5.

New Neoplasm During GH Replacement in Adults With Pituitary Deficiency Following Malignancy: A KIMS Analysis.

Krzyzanowska-Mittermayer K, Mattsson AF, Maiter D, Feldt-Rasmussen U, Camacho-Hübner C, Luger A, Abs R.

J Clin Endocrinol Metab. 2018 Feb 1;103(2):523-531. doi: 10.1210/jc.2017-01899.

PMID:
29228199
6.

Allergic and non-allergic skin reactions associated with growth hormone therapy: elucidation of causative agents.

Mehta S, Oza V, Potashner R, Zamora P, Raisingani M, Shah B.

J Pediatr Endocrinol Metab. 2018 Jan 26;31(1):5-11. doi: 10.1515/jpem-2017-0309. Review.

PMID:
29197220
7.

Pharmacovigilance of Biologics in a Multisource Environment.

Sagi S, Cohen HP, Woollett GR.

J Manag Care Spec Pharm. 2017 Dec;23(12):1249-1254. doi: 10.18553/jmcp.2017.23.12.1249.

8.

Reversible brain lesion following growth hormone replacement therapy in an adolescent.

Hadjipanayis A, Efstathiou E, Theophilou L, Chrousos G.

BMJ Case Rep. 2017 Nov 14;2017. pii: bcr-2017-221885. doi: 10.1136/bcr-2017-221885.

PMID:
29141928
9.

Efficacy and safety of two doses of Norditropin® (somatropin) in short stature due to Noonan syndrome: a 2-year randomized, double-blind, multicenter trial in Japanese patients.

Ozono K, Ogata T, Horikawa R, Matsubara Y, Ogawa Y, Nishijima K, Yokoya S.

Endocr J. 2018 Feb 26;65(2):159-174. doi: 10.1507/endocrj.EJ17-0313. Epub 2017 Nov 7.

10.

Cardiovascular risk factors and carotid intima media thickness in young adults born small for gestational age after cessation of growth hormone treatment: a 5-year longitudinal study.

van der Steen M, Kerkhof GF, Smeets CCJ, Hokken-Koelega ACS.

Lancet Diabetes Endocrinol. 2017 Dec;5(12):975-985. doi: 10.1016/S2213-8587(17)30311-X. Epub 2017 Nov 1.

PMID:
29102566
11.

Persistent de Quervain tenosynovitis induced by somatotropin treatment.

Yurdakul OV, Aytüre L, Yalçinkaya EY.

J Pediatr Endocrinol Metab. 2017 Oct 26;30(11):1223-1226. doi: 10.1515/jpem-2017-0085.

PMID:
28988225
12.

MECHANISMS IN ENDOCRINOLOGY: Clinical and pharmacogenetic aspects of the growth hormone receptor polymorphism.

Boguszewski CL, Barbosa EJL, Svensson PA, Johannsson G, Glad CAM.

Eur J Endocrinol. 2017 Dec;177(6):R309-R321. doi: 10.1530/EJE-17-0549. Epub 2017 Sep 13. Review.

PMID:
28904008
13.

Influence of growth hormone treatment on radiographic indices of the spine: propensity-matched analysis.

Yun YH, Kwon SS, Koh Y, Kim DJ, Ahn J, Lee SY.

J Orthop Surg Res. 2017 Sep 6;12(1):130. doi: 10.1186/s13018-017-0630-z.

14.

Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database.

Petrossians P, Daly AF, Natchev E, Maione L, Blijdorp K, Sahnoun-Fathallah M, Auriemma R, Diallo AM, Hulting AL, Ferone D, Hana V Jr, Filipponi S, Sievers C, Nogueira C, Fajardo-Montañana C, Carvalho D, Hana V, Stalla GK, Jaffrain-Réa ML, Delemer B, Colao A, Brue T, Neggers SJCMM, Zacharieva S, Chanson P, Beckers A.

Endocr Relat Cancer. 2017 Oct;24(10):505-518. doi: 10.1530/ERC-17-0253. Epub 2017 Jul 21.

15.

Evaluation of depressive mood and cognitive functions in patients with acromegaly under somatostatin analogue therapy.

Alibas H, Uluc K, Kahraman Koytak P, Uygur MM, Tuncer N, Tanridag T, Gogas Yavuz D.

J Endocrinol Invest. 2017 Dec;40(12):1365-1372. doi: 10.1007/s40618-017-0722-y. Epub 2017 Jun 28.

PMID:
28660605
16.

Long-Term Follow-up of a Case with Proprotein Convertase 1/3 Deficiency: Transient Diabetes Mellitus with Intervening Diabetic Ketoacidosis During Growth Hormone Therapy.

Gönç EN, Özön A, Alikaşifoğlu A, Kandemir N.

J Clin Res Pediatr Endocrinol. 2017 Sep 1;9(3):283-287. doi: 10.4274/jcrpe.3986. Epub 2017 Jun 7.

17.

Mortality in Children Receiving Growth Hormone Treatment of Growth Disorders: Data From the Genetics and Neuroendocrinology of Short Stature International Study.

Quigley CA, Child CJ, Zimmermann AG, Rosenfeld RG, Robison LL, Blum WF.

J Clin Endocrinol Metab. 2017 Sep 1;102(9):3195-3205. doi: 10.1210/jc.2017-00214.

PMID:
28575299
18.

Ten years of biosimilars in Europe: development and evolution of the regulatory pathways.

Schiestl M, Zabransky M, Sörgel F.

Drug Des Devel Ther. 2017 May 16;11:1509-1515. doi: 10.2147/DDDT.S130318. eCollection 2017. Review.

19.

Ten years of biosimilar recombinant human growth hormone in Europe.

Saenger P.

Drug Des Devel Ther. 2017 May 16;11:1505-1507. doi: 10.2147/DDDT.S130317. eCollection 2017. Review.

20.

Ten years of clinical experience with biosimilar human growth hormone: a review of safety data.

Borrás Pérez MV, Kriström B, Romer T, Walczak M, Höbel N, Zabransky M.

Drug Des Devel Ther. 2017 May 16;11:1497-1503. doi: 10.2147/DDDT.S130909. eCollection 2017. Review.

Supplemental Content

Loading ...
Support Center